This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -5.45% and 18.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for EyePoint Pharmaceuticals (EYPT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 44.44% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
by Zacks Equity Research
Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 31.3% upside potential for EyePoint Pharmaceuticals (EYPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Exelixis (EXEL) Tops Q4 Earnings Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 6.45% and 0.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 77.1% in EyePoint Pharmaceuticals (EYPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
by Zacks Equity Research
EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
Does EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 336.1% in EyePoint Pharmaceuticals (EYPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -248.78% and 88.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Down -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 13.24% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?
by Zacks Equity Research
Provention Bio, Inc. (PRVB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.